NGS

Massive Bio and Foundation Medicine Partner to Optimize Clinical Trial Recruitment and Enrollment to Expand Access to Precision Cancer Care

Retrieved on: 
Friday, September 13, 2024
Technology, Clinical Trials, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Data Management, Oncology, Artificial Intelligence, Foundation Medicine, Patient, Roger Hawkins (drummer), Physician, Clinical trial, AI, NGS, Senior, Partnership, Cancer, MD, Multimedia, Medical imaging

Massive Bio, a cutting-edge AI driven clinical trial matching platform provider, and Foundation Medicine, Inc. today announced a strategic collaboration to increase patient access to cutting edge clinical trials.

Key Points: 
  • Massive Bio, a cutting-edge AI driven clinical trial matching platform provider, and Foundation Medicine, Inc. today announced a strategic collaboration to increase patient access to cutting edge clinical trials.
  • View the full release here: https://www.businesswire.com/news/home/20240913830674/en/
    Massive Bio partners with Foundation Medicine to enhance clinical trial recruitment and expand access to precision cancer care.
  • Joining forces with Foundation Medicine is pivotal as it will allow us to develop solutions to the cancer clinical trial enrollment paradox."
  • “Through this partnership with Massive Bio, we have the patient at the forefront, leveraging our combined assets and expertise to improve access to clinical trials for patients.”

Bio-Me AS Announces Appointment of Arne Materna as Co-CEO alongside Dr. Warren Flood

Retrieved on: 
Friday, September 13, 2024
Genetics, Research, DNA, University, Skin, Growth, Real-time, Disease, MIT, NGS, Microbiology, Health, Culture, Harvard Business Review, Biomass, Translation, QIAGEN, Management

OSLO, Norway, Sept. 12, 2024 /PRNewswire-PRWeb/ -- Bio-Me AS Announces Appointment of Arne Materna as Co-CEO alongside Dr. Warren Flood

Key Points: 
  • Dr. Arne Materna has been appointed Co-CEO as of July 1st, 2024 to strengthen the company's capitalization and continued commercial growth.
  • OSLO, Norway, Sept. 12, 2024 /PRNewswire-PRWeb/ -- Bio-Me AS Announces Appointment of Arne Materna as Co-CEO alongside Dr. Warren Flood
    Dr. Arne Materna has been appointed Co-CEO as of July 1st, 2024 to strengthen the company's capitalization and continued commercial growth.
  • Bio-Me AS a leading biotechnology company and test-service provider pioneering precision microbiome profiling solutions, today announced the appointment of Dr. Arne Materna as Co-CEO, joining Dr. Warren Flood in a shared leadership role effective July 1st, 2024.
  • "I am excited to support Bio-Me's continued growth with Dr. Warren Flood in a Co-CEO tandem.

Singular Genomics Receives Non-Binding Acquisition Proposal from Deerfield

Retrieved on: 
Thursday, September 12, 2024
Singular, Committee, Letter, Special, LLP, NGS, Comment, SAN, OMIC

Deerfield, an existing stockholder of the Company, indicated in its letter that it intends to invite other major stockholders and existing management to rollover their shares of common stock into the new company.

Key Points: 
  • Deerfield, an existing stockholder of the Company, indicated in its letter that it intends to invite other major stockholders and existing management to rollover their shares of common stock into the new company.
  • The Company’s board of directors previously formed a special committee of independent directors (the “Special Committee”) to evaluate and consider the Company’s strategic alternatives, which would include the proposal submitted by Deerfield.
  • There can be no assurance that any transaction will be consummated, whether involving Deerfield or any other party.
  • The Company and the Special Committee do not intend to comment further about Deerfield’s proposal unless and until the Special Committee deems further disclosure is appropriate.

SOPHiA GENETICS Announces Poster Presentations at ESMO 2024

Retrieved on: 
Thursday, September 12, 2024
Neoplasm, Research, DNA, MD Anderson Cancer Center, University, Patient, A-DNA, ESMO, Trial of the century, NGS, Congress, GENETICS, Machine learning, TRIDENT, Biology, Lung cancer, Oncology

BOSTON and ROLLE, Switzerland, Sept. 12, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, will be presenting multiple posters at the European Society for Medical Oncology (ESMO) Congress 2024 being held in Barcelona, Spain September 13-17, 2024. The ESMO Congress is a globally influential oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world.

Key Points: 
  • BOSTON and ROLLE, Switzerland, Sept. 12, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, will be presenting multiple posters at the European Society for Medical Oncology (ESMO) Congress 2024 being held in Barcelona, Spain September 13-17, 2024.
  • The ESMO Congress is a globally influential oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world.
  • This innovative device has been developed as a clinical trial assay for Boundless Bio's ongoing, first-in-human POTENTIATE Phase 1/2 clinical study of its lead ecDNA-directed therapy (ecDTx), BBI-355.
  • For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM , or connect on LinkedIn .

Thermo Fisher Scientific Announces Oncomine Clinical Research Grant Awardees, Including First Recipients in India and the Netherlands

Retrieved on: 
Wednesday, September 11, 2024
Oncology, Health, Genetics, Other Health, Other Science, Research, Science, Ovarian cancer, DNA, MRD, European, Breast, NGS, SNV, Acute lymphoblastic leukemia, CNV, Immunotherapy, Congress, Liquid biopsy, Brain, HRD, Risk assessment, Thermo Fisher Scientific, Cancer, Tata Memorial Centre, Leiden University Medical Center, Multimedia, Genome, Medicine, OCA

At the 36th annual European Congress of Pathology in Florence, Italy, Thermo Fisher Scientific, the world leader serving science, announced the latest recipients of the Oncomine Clinical Research Grant, designed to support emerging research on molecular profiling in oncology and to help democratize the future of precision medicine.

Key Points: 
  • At the 36th annual European Congress of Pathology in Florence, Italy, Thermo Fisher Scientific, the world leader serving science, announced the latest recipients of the Oncomine Clinical Research Grant, designed to support emerging research on molecular profiling in oncology and to help democratize the future of precision medicine.
  • Now in its fourth year, the grant recognizes research from Tata Memorial Centre in India; Leiden University Center in The Netherlands; Western University in Canada; and Fred Hutch Cancer Center in the U.S.
  • “This year, we saw the highest number of Oncomine Clinical Research Grant submissions since the program began in 2020.
  • It’s a clear indication of the industry-wide push to accelerate research that explores the impacts of genomic discovery,” said Jose Luis Costa, Ph.D., global director, scientific affairs, clinical next-generation sequencing and oncology, Thermo Fisher Scientific.

NeoGenomics to Present New Data at ESMO 2024, Highlighting the Value of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment

Retrieved on: 
Wednesday, September 11, 2024
Oncology, Health, Communications, General Health, Clinical Trials, Pharmaceutical, Public Relations, Investor Relations, DNA, Patient, IHC, NTRK, Diagnosis, Cancer, NEO, ESMO, NGS, Congress, Neoplasm, NSCLC, Medical imaging

NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will present three studies at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, September 13-17 (booth #438).

Key Points: 
  • NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will present three studies at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, September 13-17 (booth #438).
  • NeoGenomics' data offers key insights into circulating tumor DNA (ctDNA) analysis and next-generation sequencing (NGS), focusing on their role in early diagnosis and treatment optimization.
  • “Emerging technologies leveraging ctDNA and NGS are increasing our ability to identify cancers in high-risk patients, which was previously beyond reach,” said Dr. Nathan Montgomery, Vice President of Medical Services at NeoGenomics.
  • This Phase II trial evaluated ctDNA as a marker to guide treatment decisions in high-risk melanoma patients.

Sepsis Diagnostics Market Research, Trends and Forecasts 2024-2029 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 11, 2024
Hospitals, Pharmaceutical, Health, Medical Devices, Microbiology, Deutsch, POC, DSG, Research, Data collection, Point-of-care testing, DNA, RNA, Education, Patient, Dicarboxylic acid, Prevalence, CDC, Polymerase chain reaction, Growth, Diagnosis, NGS, Survivor, Government, Fatality, Software, Organization, Sepsis Alliance, Fungus, PCR, Sepsis, Incidence, Infection, Medicine

Global sepsis diagnostics market is expected to continue its growth trajectory due to the sustained efforts to improve healthcare infrastructure, ongoing technological advancements, and increasing awareness about sepsis.

Key Points: 
  • Global sepsis diagnostics market is expected to continue its growth trajectory due to the sustained efforts to improve healthcare infrastructure, ongoing technological advancements, and increasing awareness about sepsis.
  • Germany's sepsis diagnostics market is thriving due to its advanced healthcare system, strong research and development capabilities, and significant government and institutional support.
  • The demand for automated diagnostics in the global sepsis diagnostics market is surging due to the need for efficiency, accuracy, and rapid turnaround in diagnosing sepsis.
  • Bacterial sepsis is a significant driver of growth in the global sepsis diagnostics market due to its high prevalence and severe impact on patient outcomes.

Pillar Biosciences Partners with AstraZeneca to Help Accelerate Access to Liquid Biopsy Testing

Retrieved on: 
Tuesday, September 10, 2024
Pillar, Neoplasm, RUO, RNA, DNA, Patient, Illumina, Laboratory, Cancer, NGS, Bandwidth (signal processing), Gene, CFRNA, Liquid biopsy, Fusion, DNA sequencing, Partnership, AstraZeneca, Oncology, Pharmaceutical industry

NATICK, Mass., Sept. 10, 2024 /PRNewswire/ -- Pillar Biosciences, Inc. has entered into a strategic partnership with AstraZeneca to expand laboratory access to molecular testing, using rapid, Next Generation Sequencing (NGS)-based liquid biopsy tumor profiling panels for detection of genetic cancer variants, with an initial focus on European markets and the UK.

Key Points: 
  • Partnership aims to make liquid biopsy tumor profiling more accessible to local laboratories, clinicians and patients through rapid, affordable, kitted NGS testing solutions.
  • The work will initially leverage Pillar Biosciences oncoRevealTM Core LBx, Essential LBx, and Fusion LBx research-use-only (RUO) liquid biopsy kitted NGS panels.
  • "These kit-based methods allow a broad range of laboratories to perform high-quality NGS testing, which improves patient access to targeted therapies.
  • Pillar Biosciences sequencing panels provide rapid, simplified NGS workflows and bioinformatics, which are ideal to supporting our global efforts."

Volta Labs Announces First Customer Shipments and Expanding Preloaded App Menu

Retrieved on: 
Tuesday, September 10, 2024
Abraxis BioScience, Research, RNA, DNA, IDT, Running, Genomics, History, Doctor of Philosophy, NGS, Partnership, QIAGEN

Volta Apps are validated and optimized to meet existing sequencing requirements for optimal performance and accuracy, enabling labs to be up and running on day one.

Key Points: 
  • Volta Apps are validated and optimized to meet existing sequencing requirements for optimal performance and accuracy, enabling labs to be up and running on day one.
  • That's all history," said Udayan Umapathi, founder and CEO of Volta Labs.
  • The quickly expanding Volta Apps menu supports DNA extractions for all long- and short-read platforms, target enrichment for all short-read sequencers, as well as library prep with an app exclusively for PacBio SMRTbell technology and short-read PCR-free workflows.
  • Volta Labs is accepting orders for Callisto with special bundled pricing for customers who purchase multiple instruments - visit the website for full product information and to get in the queue.

GenomOncology Partners with Precipio to Advance Myeloid Testing and Reporting

Retrieved on: 
Tuesday, September 10, 2024
Karyotype, Clinical trial, Workflow, NGS, Quality control, FISH, IHC, Partnership, Pathology

GenomOncology, a leading provider of precision medicine software, and Precipio, a specialty cancer diagnostics company, announced their strategic partnership aimed at advancing myeloid testing and clinical genomic reporting.

Key Points: 
  • GenomOncology, a leading provider of precision medicine software, and Precipio, a specialty cancer diagnostics company, announced their strategic partnership aimed at advancing myeloid testing and clinical genomic reporting.
  • GenomOncology's Pathology Workbench will be utilized as the tertiary analysis and fully-customized clinical genomic reporting platform for Precipio's Next Generation Sequencing test for myeloid neoplasms.
  • "The collaboration with GenomOncology allows Precipio to accelerate a best-in-class clinical reporting solution in the marketplace to serve our customers," said Zaki Sabet, Chief Operating Officer at Precipio.
  • "The robust knowledgebase embedded in the GenomOncology Pathology Workbench will empower Precipio to advance variant interpretation for their NGS testing.